Welcome to the IWGT registration page
From the 23rd to the 26th August, 2022, the 8th International Workshop on Genotoxicity Testing (IWGT) will be held in Ottawa, Canada, addressing the topics detailed below. This workshop will, as usual, be organized as a satellite meeting to the International Conference on Environmental Mutagens (ICEM), held every four years. Both meetings had to be postponed by 1 year because of the COVID pandemic.
The success of these workshops is based on our ability to include experts representing regulatory agencies, academia, and industry from across the world.
Delegate registration: €250 via the tab above
• This is now a hybrid meeting. Registration is for both attendance in person and remotely. Please select your option on page 2 of the registration page when you book your pass.
• Remote attendees will not enjoy the full benefit of meeting on person. Please see our statement here for further details.
At this IWGT the following topics will be addressed:
- Transcriptomic Biomarkers
- Predictivity of in vitro Genotoxicity Testing
- Genotoxicity dose-response Analysis
- In vivo Strategies
- Statistical Approaches and Data Interpretation
Transcriptomic Biomarkers to cover the following:
- Transcriptomic biomarkers described for genotoxicity testing
- Context of use of transcriptomic biomarkers in genotoxicity testing
- Major application in genotoxicity testing, i.e. screening, hazard identification, integration in tiered testing strategies, follow up testing, potency ranking
- Data gaps to be closed for broader regulatory acceptance
- Best practice for validation/qualification of transcriptomic biomarkers
- Usability of transcriptomic biomarkers for quantitative analysis
Predictivity of in vitro Genotoxicity Testing, a mathematical modelling Approach to cover the following:
- Identification of combination(s) of in vitro tests with the highest predictive value for in vivo genotoxicity, using mathematical modelling approaches
- Uncertainty analysis associated with predictions, by using novel analyzing paradigms
- Composition of test batteries and implications for risk assessment
Genotoxicity dose-response Analysis for Potency Comparisons and Risk Assessment to cover the following:
• The BMD approach and issues related to this approach – software, model selection, model averaging, critical effect size (CES), potency ranking, etc.
• Risk assessment based on in vivo data – quantitative interpretation of in vivo dose-response data, margin of exposure (MOE) approach, health-based guidance values (HBGV) calculations
• Risk assessment based on in vitro data – quantitative interpretation of in vitro dose-response data, in vitro in vivo extrapolation (IVIVE), determination of bioactivity-exposure ratios
• Effect Severity and Interpretation of Genetic Toxicity Dose-response Data in a Human Health Context – state of the science, issues and controversy
• The rationale for quantitative analysis approach, state-of-the-science, outstanding issues that remain to be addressed
In vivo Strategies to cover the following:
- Updates on the validation of the liver and GI tract micronucleus tests
- Comparison of plasma concentrations and in vitro genotoxic concentrations for substances giving positive micronucleus results in bone marrow
- Issues related to the conduct and interpretation of the in vivo comet assay (progressing from discussions at HESI Genetic Toxicology Technical Committee)
Statistical Approaches and Data Interpretation to cover the following:
- Pairwise analyses, including factorial designs
- Trend tests
- Building and maintaining historical negative control data sets, assessing quality, and determining appropriate intervals
- Interpreting results based on the three above-mentioned pillars
In addition, two short plenary symposia will address:
- Epigenotoxicity and Germ Cell Effects to discuss heritable and transgenerational effects including DNA methylation, histone modification and sperm RNA as a messenger
- Gene Therapy to discuss the genotoxicity and carcinogenicity risk of gene therapy approaches including integration site analysis and off-target effects of genome editing technologies.
Hans-Jörg Martus (Switzerland, Chair), Andreas Zeller (Switzerland, Co-Chair), David Kirkland (UK, Co-Chair), Roland Frötschl (Germany), Bhaskar Gollapudi (USA), Timothy McGovern (USA), Kiyohiro Hashimoto (Japan), Kei-ichi Sugiyama (Japan)